Advocate Clinical Laboratories
Every Sample is a Life™

Test Bulletin

June 2026

ACL Announces Launch of AdvoOnc™ Hereditary Cancer Testing

Effective Wednesday, July 1, 2026, ACL Laboratories will begin performing the following hereditary cancer genetic testing options at ACL's Illinois Central Laboratory.

- AdvoOnc™ STAT Hereditary Breast Cancer Panel (Test Order Code LAB13131)
  - » For patients with an active breast cancer diagnosis who require expedited results to guide immediate treatment decisions, analysis of 10 genes, including *ATM, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, STK11, TP53,* will be performed with results expected in less than 7 days
  - » Providers must select one of the following concurrent testing panels for both timely and comprehensive evaluation
    - AdvoOnc™ Concurrent Common Hereditary Cancer Panel (32 additional genes)
    - AdvoOnc™ Concurrent Expanded Hereditary Cancer Panel (62 additional genes)
- AdvoOnc™ Hereditary Breast & Gyn Cancers Panel (Test Order Code LAB13117)
  - » Analyzes 19 genes; indicated for patients with a personal and/or family history limited to breast, ovarian, or uterine cancers
- AdvoOnc™ Common Hereditary Cancer Panel (Test Order Code LAB13119)
  - » Analyzes 42 genes; indicated for patients with a personal or family history of breast, ovarian, colorectal, uterine, pancreatic, renal, or stomach cancers
- Targeted familial testing for variants in hereditary cancer genes that have been reported by ACL
  - » AdvoTargeted™ Analysis SNV (Test Order Code LAB13153) - targeted analysis of single nucleotide variants
  - » AdvoTargeted™ Analysis CNV (Test Order Code LAB13154) - targeted analysis of copy number variants

Clinical Indications

- Cancer diagnosed at an early age (≤50 years)
- Multiple occurrences of the same or related cancer types within a family
- Rare cancer types (e.g., ovarian, pancreatic, or male breast cancer)
- Tumors with distinctive features (e.g., triple-negative breast cancer)
- Suspected germline variants identified through somatic tumor testing
- A known familial pathogenic variant associated with hereditary cancer
- Additional guidelines are available through the National Comprehensive Cancer Network (NCCN)

Test Methodology

- Next Generation Sequencing (NGS)

Specimen Requirements

- Preferred - One pink (K2EDTA) 6.0 mL OR Two lavender (K2EDTA) 3.0 mL
- Also accepted - One ORAcollect™ DX Buccal Swab kit or One Oragene™ DX Saliva kit (Available upon request. Contact an ACL Genetic Counselor at ACL-GeneticCounselors@aah.org)

For additional information regarding this test, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

continued...

Created: 6/2026 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer
CM-HB-2606a

Supply Ordering

- ACL Outreach Clients can order these supplies through the online supply portal (NPN360)
- Internal ACL sites can obtain supplies using the below Workday information

Collection Kit	ORAcollect™ DX Buccal Swab	ORAgene™ DX Saliva
Workday Item #	3029385	3059266
Photo		

Transport

- 5.0 mL (minimum 1.0 mL) whole blood, refrigerated
- ORAcollect™ Dx Buccal Swab kit, ambient
- Oragene™ DX Saliva kit, ambient

Unacceptable Conditions

- Clotted or hemolyzed specimens, dependent on the level of hemolysis
- Specimens collected in anticoagulants other than K2EDTA
- Fresh or frozen tissue, FFPE tissue blocks, or slides
- Decalcified tissue
- Saliva or buccal swab samples not meeting collection requirements
- Blood is not accepted for patients with a history of recent blood transfusion or an allogenic bone marrow/ stem cell transplant

Testing Schedule & Reporting

- Performed: Weekdays
- Performing Site: ACL Illinois Central Lab – Molecular Pathology
- Reporting Time: Breast STAT Final results within 7 days and Panels final with 21 days.

If you have any questions, please contact: ACL Molecular Pathology Laboratory at Rosemont (847.349.7182), or ACL Client Services (800.877.7016)

continued...

Created: 6/2026 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2606a

ACL Laboratories Discontinues Culturing of Intravascular Catheters

Effective Wednesday, June 17, 2026, ACL Laboratories discontinued culturing intravascular catheters. During this transition, the order for "Catheter tip, aerobe, bacterial culture (Test Order Code LAB8995)" will be discontinued. In addition, intravascular catheter tips sources will be removed as acceptable options from the following cultures:

Fungal Culture and Smear (Test Order Code LAB8981)

Yeast Culture (Test Order Code LAB9009)

Clinical guidelines indicating the utility of catheter tip cultures from the Infectious Disease Society of America (IDSA) are now over 15 years old and predominantly based on data from almost 50 years ago.[1] Since that time, several studies have been performed indicating that intravascular catheter tip cultures are no longer beneficial.[2-5] ACL Laboratories data demonstrates similar findings, with nearly 90 percent of catheter tip cultures providing no new clinically relevant information (i.e. negative cultures or cultures positive for an organism previously identified from a blood culture), while the remaining 10 percent are of questionable value and rarely lead to changes in patient management.

In addition to demonstrating limited value, these specimens are routinely submitted to the laboratory in a manner inconsistent with the IDSA guidelines (i.e. submitted in a manner that could lead to contamination or submitted without accompanying blood cultures).

Given the limited clinical value and the lack of adherence to submission guidelines, ACL Laboratories discontinued culture of catheter tips **effective Wednesday, June 17, 2026.** This decision has been made with support of the Advocate Health Infectious Disease, Antimicrobial Stewardship, and Pharmacy and Therapeutics Committees.

1. Mermel LA, et al. 2009. Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Updated by IDSA. Clin Inf Dis. 49: 1-45. doi: 10.1086/599376
2. Erb S. et al. 2014. Sonication for diagnosis of catheter-related infection is not better than traditional roll-plate culture: A prospective cohort study with 975 CVCs. Clin Inf Dis. 59(4): 541-4. doi: 10.1093/cid/ciu352
3. Peterson LR, et al. 2015. Nonutility of catheter tip cultures for the diagnosis of central line-associated bloodstream infections. Clin Inf Dis. 60: 492-3. doi: 10.1093/cid/ciu845
4. Lai YL, et al. 2019. Dwindling utilization of CVC tip cultures: An analysis of sampling trends and clinical utility at 128 US Hospitals 2009-14. Clin Inf Dis. 69(10): 1797-1800. doi: 10.1093/cid/ciz218.
5. Ulrich P, et al. 2022. Diagnostic and therapeutic utility of positive intravascular catheter tip cultures. Microbiol Spectrum. 10(6): 1-6. doi: 10.1128/spectrum.04022-22.

Temporary Referral of High-Sensitivity C-Reactive Protein

Effective Tuesday, June 9, 2026, ACL Laboratories temporarily referred Test Order Code LAB8506, High-Sensitivity C-Reactive Protein, to ARUP Laboratories due to a manufacturer reagent shortage.

As a result, turnaround times will be extended. Reference ranges will remain unchanged. See below for details on specimen collection requirements.

	ACL In-House Test	ARUP Laboratory
Methodology	Rate Nephelometry	Quantitative Immunoturbidimetry
Reference Range	≤ 3.0 mg/L	≤ 3.0 mg/L
Interpretive Information	CAD Risk: < 1.0 mg/L (< 0.10 mg/dL) LOW 1.0 to 3.0 mg/L (0.10 to 0.30 mg/dL) AVERAGE > 3.0 mg/L (> 0.30 mg/dL) HIGH (2X) > 10.0 mg/L (> 1.0 mg/dL) Consider other source of inflammation/infection.	hs-CRP results are used to assign a risk as follows: Less than 1.0 mg/L= Low Risk 1.0-3.0 mg/L= Average Risk Greater than 3.0 mg/L= High Risk
Specimen Collection Details (specimen type, amount)	One gold gel (SST) 3.5mL OR One red (plain) 4 mL	Serum separator tube. Also acceptable: Plasma separator tube, pink (K2EDTA), or green (lithium heparin).
Transport Temperature	Refrigerated	Refrigerated
CPT Codes	86141	86141
Turnaround Time	24 hours	3 days

continued...

Created: 6/2026 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2606a

ACL Laboratories Transitions Ceruloplasmin (Test Order Code LAB8512) testing back in-house

Effective Wednesday, June 17, 2026, ACL Laboratories transitioned Ceruloplasmin (Test Order Code LAB8512) testing back in-house after temporarily sending it to our reference laboratory.

Specimen collection requirements and reference ranges did not change; test turnaround time changed. See the chart below for details on the new method.

Ceruloplasmin		
	Former Method (Siemens Vista)	**Current Method (effective 6.17.2026) (The Binding Site – Optilite)**
Methodology	Nephelometry	Turbidimetric
Transport Requirement	Spun gel tube or aliquot with 1.0 mL (minimum 0.5 mL) serum, refrigerated	Aliquot with 1.0 mL (minimum 0.5 mL) serum, frozen
Stability	Ambient: Unacceptable Refrigerated: 1 week Frozen: 2 weeks	Ambient: Unacceptable Refrigerated: Unacceptable Frozen: 4 weeks
Reporting Time	24 hours	3 days
Performed	Daily	Weekdays

ACL Laboratories Implements Change in Method for Alpha 1 Antitrypsin (Test Order Code LAB8498)

Effective Wednesday, June 17, 2026, ACL Laboratories implemented a change in the method for Alpha 1 Antitrypsin (Test Order Code LAB8498) testing due to reagent unavailability.

Specimen collection requirements and reference ranges did not change; test turnaround time did change. See the chart below for details on the new method.

Alpha 1 Antitrypsin		
	Former Method (Siemens Vista)	**Current Method (effective 6.17.2026) (The Binding Site – Optilite)**
Methodology	Nephelometry	Turbidimetric
Transport Requirement	Spun gel tube or aliquot with 1.0 mL (minimum 0.5 mL) serum, refrigerated	Aliquot with 1.0 mL (minimum 0.5 mL) serum, frozen
Stability	Ambient: Unacceptable Refrigerated: 1 week Frozen: 2 weeks	Ambient: Unacceptable Refrigerated: Unacceptable Frozen: 2 weeks
Reporting Time	24 hours	3 days
Performed	Daily	Weekdays

For additional information regarding this test, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

continued...

Created: 6/2026 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2606a

New Orderable Code: AML - FLT3 ITD MRD by NGS

Effective Wednesday, June 17, 2026, AML-FLT3 ITD MRD by NGS (Test Order Code LAB13497) is available as an orderable test. The test information is below.

Test Information	AML – FLT3 ITD MRD by NGC
Test Order Code	LAB13497
Specimen Requirement	Whole blood 3.0 mL (minimum 1.0 mL) or Bone Marrow 1.0 mL (minimum 0.3 mL)
Collection Tube	Whole blood: One lavender (K2EDTA) 3.0 mL **OR** Bone marrow: One lavender (K2EDTA) 3.0 mL
Temperature	Refrigerated
Stability	7 days
Methodology	Next Generation Sequencing
TAT	Final within 15 days
Performing Laboratory	LabPMM Invivoscribe via ARUP

Beta – Trace Protein, Body Fluid

Effective Wednesday, June 17, 2026, the following send out assays have been updated.

Test Information	Current (deactivated 6.17.2026)	Replacement (activated 6.17.2026)
Test Name	Beta 2 Transferrin	Beta-Trace Protein, Body Fluid
Tet Order Code	LAB9385	LAB13487
Performing Lab	ARUP	Mayo
Specimen Type	Aural or nasal fluid	Body Fluid 0.5 mL (minimum 0.1 mL)
Collection container	Sterile Container	Sterile Container
Temperature	Refrigerated	Refrigerated
Stability	2 weeks	14 days
Methodology	Qualitative Immunofixation Electrophoresis	Nephelometry
TAT	Final within 6 days	Final within 5 days

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

continued...

Created: 6/2026 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2606a

Alkaline Phosphotase, Total and Isoenzymes, Serum

Effective Wednesday, June 17, 2026, the following send out assays have been updated.

Test Information	Current (deactivated 6.17.2026)	Replacement (activated 6.17.2026)
Test Name	Alkaline Phosphatase Isoenzymes	Alkaline Phosphatase, Total and Isoenzymes, Serum
Test Order Code	LAB12286	LAB13462
Performing Lab	ARUP	Mayo
Specimen Type	Serum	Serum 1.0 mL
Collection container	Gold Gel	Gold Gel
Temperature	Refrigerated	Frozen
Stability	1 week	14 days
Methodology	Quantitative Heat Inactivation/ Enzymatic Assay	ALP: Colorimetric ALPI: Electrophoresis
TAT	Final within 6 days	Final within 7 days

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

Created: 6/2026 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2606a